Oral Multi-kinase inhibitor for Metastatic Colorectal Cancer
Created 3 weeks ago by anniepery

Regorafenib (Stivarga), specifically is an oral multi-kinase inhibitor, which was developed by Bayer. It primarily targets angiogenic, stromal and oncogenic RTK (Receptor Tyrosine Kinase). The drug regorafenib 40 mg demonstrates anti-angiogenic activity because of its dual-targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since the year 2009, this agent has been studied as a potential treatment option in multiple tumor types. The recommended dose of regorafenib is 160 mg, which should be taken orally, once daily with food (a low-fat breakfast) for the first 21 days of each 28-day cycle. Regorafenib may be responsible for causing fetal harm when administered to pregnant women.